| scholarly article | Q13442814 |
| P2093 | author name string | W Mau | |
| A Boonen | |||
| P433 | issue | 4 Suppl 55 | |
| P921 | main subject | ankylosing spondylitis | Q52849 |
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | S112-7 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | Clinical and Experimental Rheumatology | Q15759225 |
| P1476 | title | The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis | |
| P478 | volume | 27 |
| Q35116409 | An evaluation of a biopsychosocial framework for health-related quality of life and disability in rheumatoid arthritis |
| Q37583028 | Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea. |
| Q49387423 | Economic evaluation of spondyloarthritis: economic impact of diagnostic delay in Italy |
| Q37143729 | Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate |
| Q52597260 | Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study. |
| Q36135031 | Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study |
| Q34818891 | Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised pla |
| Q31119751 | Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction |
| Q42110795 | Periocular and intra-articular injection of canine adipose-derived mesenchymal stem cells: an in vivo imaging and migration study |
| Q34523450 | Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70 |
| Q36059239 | The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries |
| Q37947117 | The balance of tissue repair and remodeling in chronic arthritis |
| Q39248083 | Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study |
Search more.